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Dr Yves d’Udekem (Melbourne, Australia). We reviewed all
the results with Christian Brizard, and all the comments and ques-
tions were discussed. What is your median time of follow-up?
Dr Mussa. Three years.
Dr d’Udekem. It was actually 2.3 years in your article. And the
reason for that is probably because of one of the flaws of your study.
You stopped the follow-up at the first intervention, which is a prob-
lem, because if you have an early intervention you don’t know
about the outcome of these patients.
In the follow-up study of the Melbourne patients that we did with
similar approaches, similar technique, even similar surgeons at
times, we gathered a median time of follow-up of 15 years. Approx-
imately 15% of the patients who had a definitive repair died after
the repair. The median time to death was 4 years, which means
half of the patients died 4 years after the repair. If your follow-up
is approximately 2.5 years, then you may miss half, or who knows,
maybe three quarters of the deaths after repair. And having a study
for which your conclusion is based solely on survival, it’s a very
annoying fact.
Disputes are often due to miscommunication. I think if we want
to progress in that debate of MAPCAs and unifocalization, we have
to clarify some terminology and in particular the term ‘‘unifocaliza-
tion.’’ When you go into the lung’s hilum, you dissect a confluent
intrapulmonary artery, and you put a shunt there or you put a tube
that you connect to the RV, I bet that you’re going to call that uni-
focalization. I think I would call it rehabilitation of the native PAs. I
think that we all agree that you have to recruit these intrapulmonary
native PAs. But the real question is, what happened to the collateral
arteries that you detach from the aorta and incorporate in that pul-
monary arborization?
Do you have an idea of what proportion of patients underwent
translocation of collateral arteries; and if you know that, do you
have angiographic control studies of these translocated collateral
arteries?
Dr Mussa. Well, you remember from our presentation that we
had reintervened on approximately all of our patients. But in terms
of reintervention on the MAPCAs, there weren’t many. Like I said,
only 1 stent and 2 balloons. There were some surgical interventions
of the proximal portions of those, but I don’t know the exact num-
bers of those, but we intervened on approximately 30 main PAs.
Dr d’Udekem. I’m afraid it’s difficult to reintervene on a collat-
eral if it’s not existent anymore; that’s my concern and why I think
we need to have these angiographic data.
In your conclusion, I quote, you said, ‘‘MAPCAs are there to be
recruited.’’ We thought that was a very firm statement expressed
like that. We have looked at your results, and we thought there
may be some problems with that statement.
First, as I mentioned, the conclusion is based on survival, and
we’re not sure exactly yet about the survival. It may be excellent,
but I think that remains to be demonstrated.
Second, you may want to use more equipoise in the interpreta-
tion of your results. For example, if you look at the characteristics
of your patients, by the end of the study you have 50 of 216 patients
left with a palliation. I think that’s an important proportion. You
may as well conclude in your study that you achieve a good survival
in these patients if you leave a lot of them palliated. Or if you have
only collateral translocations in, I don’t know, 5060 patients, whichgery c December 2009
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DI guess it is, you can say, okay, you have better survival if you
rehabilitated native PAs. Obviously these are just suggestions.
I’m wondering if these patients are not sicker than they appear to
be, and, especially about what you say, they have a high rate of in-
tervention, 80% reintervention at 5 years. So I’m sure you don’t do
unnecessary reintervention. So one can suspect that a lot of these
patients may have elevated right ventricular to left ventricular pres-
sure ratio, and I think that question should be solved.
There were angiographies for every single one of those undergo-
ing these 196 reinterventions. It is difficult to show that translocated
collateral arteries disappear. It might be much easier to demonstrate
angiographically that these translocated collateral arteries remain
patent. So if that is the case, it should be relatively easy to show an-
giograms with beautiful pulmonary arborization after translocation
of the collateral arteries.
Do you have further data analysis or further evidence, particu-
larly angiographic, to substantiate the statement that ‘‘MAPCAs
are there to be recruited,’’ or do you want to soften up a little bit
that statement?
Dr Mussa. I’ll start with the RV-LV pressure ratio that you
asked about first. Certainly that’s an excellent question. It’s data
that we are looking at, and we have yet to come to a conclusion
as to what our RV-LV pressure ratios are doing over time.
In terms of angiographic follow-up to examine the MAPCAs
that we have recruited, unfortunately, a lot of our patients are lo-
cated all over Europe, and it’s difficult to get angiographic data
on all of those patients to see exactly how those MAPCAs have
fared over time. So I’m sorry, we don’t have that data.
Dr Frank Hanley (Stanford, Calif). Congratulations on a phe-
nomenal series of patients. Just to weigh in on this question of
whether MAPCAs are valuable or not, we have an approximateThe Journal of Thoracic and Car21% incidence of completely absent intrapericardial PAs, meaning
not a string-like, not even a cord-like structure, but completely ab-
sent, including absence of confluent hilar areas. That 21% inci-
dence translates into more than 100 patients with unifocalized
vessels and no intrapericardial PAs. With 8-year mean follow-up,
and follow-up up to 15 years, that subgroup is no different than
the larger population. So it doesn’t play out as a risk factor for either
RV-LV pressure ratio or survival.
The important message is, if patients can survive up to 15 years
after unifocalization and repair when there were no true PAs, only
collaterals, with the same outcome as those who have true PAs, it is
unequivocal that collaterals are of value. This is the case when there
are absent PAs. It follows that collaterals will be of benefit in any
case where the PAs, if present, do not arborize normally.
Dr Mussa. Thank you.
Dr James Tweddell (Milwaukee, Wis). Among the patients who
were unifocalized and in whom the VSD was left open, you used 2
strategies to supply pulmonary blood flow, an RV-PA conduit or
a Blalock-Taussig shunt. How did you make that decision? And
within that group, did you notice any difference in the likelihood
of subsequent VSD closure between those 2 strategies?
Dr Mussa. First, I would just say that of those patients with the
VSD left open and the use of the Blalock-Taussig shunt, the use of
shunts was largely historical in this series and was performed early
on more than now. Can I just get your second question again,
please?
Dr Tweddell. Among those 2 strategies of supplying pulmonary
blood flow in the patients whose VSDs were open, did you identify
a difference in the likelihood of subsequent VSD closure between
those 2 strategies?
Dr Mussa. The simple answer is no, we didn’t.diovascular Surgery c Volume 138, Number 6 1275
